Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings this Thursday morning. Here’s what you need to know.
Collegium Pharmaceutical beat analysts’ revenue expectations by 2.3% last quarter, reporting revenues of $177.8 million, up 22.7% year on year. It was a satisfactory quarter for the company, with a decent beat of analysts’ EPS estimates.
Is Collegium Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Collegium Pharmaceutical’s revenue to grow 24.2% year on year to $180.4 million, improving from the 7.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.85 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Collegium Pharmaceutical has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Collegium Pharmaceutical’s peers in the branded pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Supernus Pharmaceuticals’s revenues decreased 1.7% year on year, beating analysts’ expectations by 7.4%, and Bristol-Myers Squibb reported flat revenue, topping estimates by 7.8%. Bristol-Myers Squibb traded down 3.9% following the results.
Read our full analysis of Supernus Pharmaceuticals’s results here and Bristol-Myers Squibb’s results here.
The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the branded pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Collegium Pharmaceutical’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $42.75 (compared to the current share price of $31.10).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.